Long-term follow-up of people treated with Kymriah for blood cancers
Follows people with B-cell leukemia or lymphoma treated with Kymriah over time.
Plain-language title generated from the registry record
Registry title: Long-term Follow up Local Registry Study of Kymriah in South Korea
Key facts
- Where
- Bundang Gu, Busan, Gyeonggi-do, Incheon, Jeollanam, Seongnam-si, Seoul, and Ulsan, South KoreaSee the 8 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 0 and 100 years old?
Source: NCT06785818, who can take part
Where in South Korea
- Bundang GuBundang Gu, South KoreaTaking people
- BusanBusan, South KoreaTaking people
- Gyeonggi-doGyeonggi-do, South KoreaTaking people
- IncheonIncheon, South KoreaTaking people
- JeollanamJeollanam, South KoreaTaking people
- Seongnam-siSeongnam-si, South KoreaTaking people
- SeoulSeoul, South KoreaTaking people
- UlsanUlsan, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06785818
- Record updated
- 30 July 2026
- Original description
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.Read full original descriptionShow less
A Registry to Assess Long-Term Safety of Patients With B-Lymphocyte Malignancies Treated With Tisagenlecleucel in South Korea
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.
Inclusion: Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS); Consented to data collection.
Exclusion: Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B.